Kim Sablich: Yes, sure, Rob. So I’ll say that we’ve had very nice growth in the three indicated populations as well as growth over time and the base of prescribers that are utilizing Epidiolex. And what we see traditionally as our customers get more and more experience with the product, usually starting in the three indications they see what it can do for their patients in terms of seizure control and now beyond seizure control that frankly, they’ve been hearing about from caregivers since day one of the launch. And this really gives them the confidence to start using it more broadly across the section of various seizure types and so forth. So we’re clearly not promoting it outside that, but this is what we hear from the providers once they get the experience they see the efficacy, they do start to utilize it earlier and more broadly across their patient population.
And really, the data, as we’ve talked about, that we’ve been sharing to really increase the efficacy perception of the product, the clobazam combination data in and of itself, get them to stop and think about why am I reserving this for certain patient types. Most of my patients are on clobazam, most of them could still benefit from additional seizure control or beyond seizure benefits and it really gets them to start thinking about I should be using this more and more and more of these patients that are taking clobazam.
Operator: Thank you. Our next question comes from the line of Jeff Hung with Morgan Stanley. Your line is now open.
Jeff Hung: For Rylaze, you’ve talked about focusing on adolescents and young adults. Can you talk a little bit more about how that’s going and how much of that opportunity remains to be addressed?
Bruce Cozadd: Kim?
Kim Sablich: Sure, love to. I love talking about Rylaze. What we’ve really seen with Rylaze is just lack of excitement in general. And I think as we told you early on, it didn’t take very long for health care providers to have confidence in the supply and to return to best clinical practice in terms of switching patients at the first sign of hypersensitivity. At this point in the pediatric market, it’s been added almost universally to the protocols in that setting. So at the beginning of this year, we did tell you that we were looking to start trying to expand the adolescent and young adult market. There was quite a bit of usage — a fair amount of usage of the product in adolescents and young adults that were being treated in the pediatric center per pediatric protocol but the adult centers were less educated, familiar and experienced with using Rylaze in this setting.
And so we’ve gone out there this year. We have now spent two quarters educating them on the product, about the importance of switching as quickly as possible when they see a hypersensitivity reaction. And we see nice orders coming through and a nice growth rate happening in this setting. So we don’t think we’re done. We haven’t gotten all of these centers to start using it. Some of them are still dabbling. So there definitely is some more growth to be had there. And I think it’s important to remember that in the adult setting, because this is a weight-based product, the average dose is higher than in the pediatric center. So each adult patient is worth more. So, we’re really pleased with Rylaze at this date, but we think there’s a little bit more room to grow here in the U.S. and then, of course, ex-U.S.
Operator: Thank you. Our next question comes from the line of Balaji Prasad with Barclays. Your line is now open.
Unidentifed Analyst: This is Xiao on for Balaji. Just a quick one on your OX2R program. On the data for TAK-994 that was recently published on New England Journal of medicine and the factor for liver toxicity for TAK-994 was the impact of reactive metabolics. So Takeda also mentioned that TAK-861 and TAK-994 do have the overlapping mitabiotic pathways. So do you think JZP441 is well differentiated with TAK-994 to avoid this issue?
